Scientific Online Resource System

International Bulletin of Otorhinolaryngology

Our experience in intratympanic vs intravenous steroids for Idiopathic Sudden Sensorineural Hearing Loss

S. Kosyakov, A. V. Gunenkov, A. G. Atanesyan, E. R. Ashkhatunyan

Abstract

Background. Currently the treatment idiopathic sudden sensorineural hearing loss by steroids is considered to be the most effective and common one. It is established that intratympanic administration of steroids, even in small quantities, results in its higher concentration in the end organ compared with systemic administration. Therefore drugs that are used topically in low doses are to be preferred. We will discuss our experience for intratympanic treatment as opposed to systemic steroids
Methods. 73 patients were observed in the study. 24 patients among them were treated with intratympanic dexamethasone over a period of 6 months. 24 patients were treated with steroids and reologic substances 25 patients were treated with intravenous dexamethasone only over a period of 10 days. Pretreatment and 1-, 3-, 6-month post-treatment using pure-tone audiograms were compared.
Results. Intratympanic and systemic therapy did not show any differences in the treatment efficiency during the first month. But intratympanic steroid therapy resulted in higher efficacy after prolonged treatment, i.e. 6 months. No differences were found between groups treated with systemic steroid monotherapy or with steroids and reologic substanses.
Conclusions. Long-term IT steroid therapy over a period of 6 months showed a more noticeable efficacy than with steroids and reologic substanses and systemic steroid monotherapy. Our experience confirms that IT therapy can be used as the primary method for treatment for patients with contraindications of systemic steroid therapy and for those with mainly high-frequency sensorineural hearing loss.

Full Text


References

Stachler JR, Chandrasekhar S, Archer S et al. Clinical practice guideline: sudden hearing loss. Otolaryngol Head Neck Surg. 2012 Mar; 146 (3 Suppl):1-35.

Powell-Tuck J, Bown RL, Lennard-Jones JE. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol. 1978;13(7):833-837.

Rauch SD. Clinical practice: idiopathic sudden sensorineural hearing loss. N Engl J Med. 2008;359(8):833-840.

Parnes LS, Sun AH, Freeman DJ. Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope. 1999;109(7, pt 2):1-17.

Chandrasekhar SS. Intratympanic dexamethasone for sudden sensorineural hearing loss: clinical and laboratory evaluation. Otol Neurotol 2001;22(1):18-23.

Rauch SD, Halpin CF, Antonelli PJ et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA. 2011 May 25;305(20):2071-9.

Plontke SK, Siedow N, Wegener R, Zenner HP, Salt AN. Cochlear pharmacokinetics with local inner ear drug delivery using a three-dimensional finite-element computer model. Audiol Neurotol 2007;12(1):37-48.

Plontke SK, Biegner T, Kammerer B, Delabar U, Salt AN. Dexamethasone concentration gradients along scala tympani after application to the round window membrane. Otol Neurotol 2008;29(3):401-6.

Plontke SK, Salt AN. Quantitative interpretation of corticosteroid pharmakokinetics in innner ear fluids using computer simulations. Hear Res 2003;182(1-2):34-42.

Plontke SK, Lцwenheim H, Mertens J et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope 2009;119(2):359-69.

Salt AN. Dexamethasone concentration gradients along scala tympani after application to the round window membrane. Otol Neurotol 2008;29(3):401-6.

Banerjee A, Parnes LS. Intratympanic corticosteroids for sudden idiopathic sensorineural hearing loss. Otol Neurotol 2005;26(5):878-81.

Gallant C, Kenny P. Oral glucocorticoids and their complications. A review. J Am Acad Dermatol 1986;14(2 Pt 1):161-77.

Salt AN, Plontke SK. Local inner-ear drug delivery and pharmakokinetiks. Drug Discov Today 2005;10(19):1299-306.

Byl FM. Sudden hearing loss: eight years' experience and suggested prognostic table. Laryngoscope 1984;94(5 Pt 1):647-61.

Battaglia A, Burchette R, Cueva R. Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otol Neuroto. 2008;29(4):453-60.

Loughan S. Management of sudden sensorioneural hearing loss: a consultant survey. J Laryngol Otol 2000;114(11):837-9.

Mattox DE, Simmons FB. Natural history of sudden sensorioneural hearing loss. Ann Otol Rhinol Laryngol 1977;86 (4 Pt 1):463-80.

Stokroos RJ, Albers FW, Schirm J. Therapy of idiopathic sudden sensorioneural hearing loss: antiviral treatment of experimental herpes simplex virus infection of the inner ear. Ann Otol Rhinol Laryngol 1999;108(5):423-8.

Zhao H, Zhang TY, Jing JH, Fu YY, Luo JN. Prognostic factors for patients with the idiopathic sudden sensorineural hearing loss [in Chineese]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2008;43(9):660-4.

Ho HG, Lin HC, Shu MT, Yang CC, Tsai HT. Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment. Laryngoscope 2004;114(7):1184-9.

Herr BD, Marzo SJ. Intratympanic steroid perfusion for refractory sudden sensorineural hearing loss. Otolaryngol Head Neck Surg 2005;132(4):527-31.

Choung YH, Park K, Shin YR, Cho MJ. Intratympanic dexamethazone injection for refractory sudden sensorineural hearing loss. Laryngoscope 2006;116(5):747-52.

Lefebvre PP, Staecker H. Steroid perfusion of the inner ear for sudden sensorineural hearing loss after failure of conventional therapy: a pilot study. Acta Otolaryngol 2002;122(7):698-702.

Plontke S, Lцwenheim H, Preyer S et al. Outcomes research analysis of continuous intratympanic glucocorticoid delivery in patients with acute severe to profound hearing loss: basis for planning randomized controlled trials. Acta Otolaryngol 2005;125(8):830-9.

Plaza G, Herrбiz C. Intratympanic steroids for treatment of sudden hearing loss after failure of intravenous therapy. Otolaryngol Head Neck Surg 2007;137(1):74-8.

Peng Y, Xiong S, Cheng Y, Qi YF, Yang Y. Clinical investigation of different routes of administration of dexamethasone on sudden deafness [in Chineese]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2008;22(10):442-5.

Kakehata S, Sasaki A, Oji K, et al. Comparison of intratympanic and intravenous dexamethasone treatment of sudden sensorineural hearing loss with diabetes. Otol Neurotol 2006 ;27(5):604-8.

Alexander TH, Weisman MH, Derebery JM, et al. Safety of high-dose corticosteroids for the treatment of autoimmune inner ear disease. Otol Neurotol. 2009;30(4):443-448.

McDonough AK, Curtis JR, Saag KG. The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol. 2008;20(2):131-137.

Novoa E, Gaertner M, Henzen C. Systemic effects of the intratympanic dexamethasone therapy. Endocr Connect. 2014;1 3(3):127-131.

Chandrasekhar SS, Rubinstein RY, Kwartler JA et al. Dexamethasone pharmakineticsin the inner ear: comparison of the route of administration and use of facilitating agents. Otolaryngology-Head and Neck surgery. 2000;4:521-528.

Bird PA, Begg EJ, Zhang M, Keast AT, Murray DP, Balkany TJ. Intratympanic versus intravenous delivery of methylprednisolone to cochlear perilymph. Otology Neurootol. 2007:8:1124-1130.




DOI: http://dx.doi.org/10.14748/orl.v11i3.6862

Refbacks

Font Size


|